Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

MC1633 Phase II Trial to Evaluate the Efficacy of the FASN Inhibitor, TVB-2640, in Combination With Trastuzumab Plus Paclitaxel or Endocrine Therapy in Patients With HER2+ Metastatic Breast Cancer Resistant to Trastuzumab-Based Therapy

NCT03179904 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT03179904
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03179904 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
MC1633 Phase II Trial to Evaluate the Efficacy of the FASN Inhibitor, TVB-2640, in Combination With Trastuzumab Plus Paclitaxel or Endocrine Therapy in Patients With HER2+ Metastatic Breast Cancer Resistant to Trastuzumab-Based Therapy
Lead sponsor
Mayo Clinic
Phase
Phase 2
Overall status
Completed
Start date
August 3, 2017
Completion date
March 13, 2026
Enrollment
17 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

advanced breast carcinoma, anatomic stage iii breast cancer ajcc v8, anatomic stage iv breast cancer ajcc v8, her2-positive breast cancer, her2-positive breast carcinoma